DHCPL

Communicating safety information to patients and healthcare professionals is a public health responsibility, and is essential in promoting the safe and rational use of medicines, and preventing harm from adverse reactions.

This webpage serves to provide the public and healthcare professionals with easy access to important drug safety information, as approved by SAHPRA. Safety alerts provide important information and recommendations about therapeutic products; however, it does not necessarily imply that a product is considered unsafe.

Fluracedyl 250/500/1000/5000

Toggle Expand / Collapse

Fluoropyrimidine containing medicines and related substances: increased drug exposure and toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.

View PDF

Teva Carbilevo 25/100; 25/250

Toggle Expand / Collapse

Dopaminergic medicines used in the treatment of Parkinson’s Disease: risk of dopamine dysregulation syndrome (DDS).

View PDF

Fluoroquinolone antibiotics: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones.

View PDF

Increased risk of subclinical acute interstitial nephritis associated with the use of proton pump inhibitors (PPIs) leading to acute kidney injury and/or chronic renal failure.

View PDF